Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
종목 코드 EVOK
회사 이름Evoke Pharma Inc
상장일Sep 25, 2013
CEOD'Onofrio (Matthew J)
직원 수3
유형Ordinary Share
회계 연도 종료Sep 25
주소420 Stevens Avenue
도시SOLANA BEACH
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호92075
전화18583451494
웹사이트https://evokepharma.com/
종목 코드 EVOK
상장일Sep 25, 2013
CEOD'Onofrio (Matthew J)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음